Gene Bridges licenses Red/ET Recombineering to Novozymes

Gene Bridges GmbH, the recombineering company, today announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.

Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed.

Dr. Alan Berry, Director, Microbial Physiology and HTS at Novozymes Inc. in Davis, CA said: “The Red/ET system is a very powerful technology, and we look forward to using it to accelerate our strain development efforts.”

Dr. Tim Zeppenfeld, Business Development Manager at Gene Bridges GmbH, commented: "We are very pleased to add Novozymes to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in metabolic engineering and is used worldwide in industry and academia."

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:

• Independent of restriction sites
• No size limits
• No unwanted mutations
• Rapid

Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes.